ICU Medical, Inc. — FY2011 Form 10-K
Reporting period: Fiscal year ended December 31, 2011. This is an annual filing, not a standalone fourth-quarter filing; quarterly Q4 figures are identified below. Financial amounts are in U.S. dollars.
Business context
ICU Medical develops and manufactures medical devices for infusion therapy, critical care and oncology, including needlefree connectors, custom infusion sets, monitoring systems and closed hazardous-drug delivery products. Products are sold in more than 50 countries. Hospira remained the largest customer, representing 42% of FY2011 revenue; its supply and distribution agreements extend through 2018.
Financial performance and liquidity
| Metric | FY2011 | FY2010 | Change |
|---|---|---|---|
| Total revenue | $302.2 million | $283.0 million | +6.8% |
| Gross profit / margin | $142.4 million / 47% | $129.0 million / 46% | Margin +1 percentage point |
| Operating income | $65.2 million | $47.7 million | +36.8% |
| Net income | $44.7 million | $29.9 million | +49.3% |
| Diluted EPS | $3.15 | $2.16 | +$0.99 |
| Operating cash flow | $64.5 million | $33.1 million | +$31.4 million |
| Cash, cash equivalents and investments | $160.0 million | $93.4 million | +$66.6 million |
| Working capital | $231.1 million | $179.5 million | +$51.6 million |
- FY2011 revenue by product group: infusion therapy $198.9 million; critical care $61.4 million; oncology $24.4 million. CLAVE products alone contributed $109.2 million, or 36% of revenue.
- Cash from operations was $64.5 million; investing activities used $45.7 million and financing activities provided $2.1 million. Capital expenditures were $15.8 million.
- Total liabilities were approximately $40.5 million, including current liabilities of $29.3 million and deferred tax and income-tax liabilities. The balance sheet reports no borrowings or debt.
- Q4 FY2011 revenue was $76.5 million and net income was $17.8 million, versus $75.1 million and $9.7 million, respectively, in Q4 FY2010. The Q4 earnings comparison includes the Orbit product-line sale gain.
Material changes versus prior year
- Revenue grew 6.8%, led by oncology (+34% to $24.4 million) and infusion therapy (+6% to $198.9 million). Critical care sales fell 4% to $61.4 million, primarily reflecting competition, lower unit sales and midyear price reductions.
- International sales increased to $73.7 million from $64.7 million; the stronger euro added an estimated $1.9 million to FY2011 sales compared with FY2010 exchange rates.
- Gross margin improved to 47% from 46%, supported by favorable product mix and lower freight costs, partly offset by higher Slovakia manufacturing and raw-material costs and lower critical-care pricing.
- Reported operating income included a $14.2 million gain on the November sale of the Orbit diabetes infusion-set product line and a $2.5 million legal-settlement credit. Excluding these credits, operating income was approximately $48.5 million, only modestly above FY2010’s $47.7 million.
- SG&A rose to $85.3 million from $76.6 million, and R&D rose to $8.6 million from $4.7 million. The company cited sales-force expansion, compensation, IT and product-development spending, as well as one-time retention-plan costs.
- The filing restates previously issued FY2009 and FY2010 results for underestimated rebate reserves: revenue was reduced by $2.6 million in 2009 and $1.6 million in 2010. The cumulative reserve adjustment at December 31, 2010 was $4.2 million. 2010 quarterly results were also retrospectively adjusted.
Outlook, commentary and risks
- Management expected modest FY2012 increases in Hospira sales, non-Hospira domestic sales and infusion therapy, and moderate international growth. It expected significant oncology growth, but lower critical-care sales due to price reductions and competition. These are estimates, not guarantees.
- Management estimated FY2012 SG&A at 26.5%–27.0% of revenue, R&D at 2.5%–3.0%, an effective tax rate of about 35%, and capital expenditures of $13–$18 million.
- The company said existing cash, investments and expected operating cash flow should fund operations for at least the next 12 months. It held $11.0 million of cash and cash equivalents outside the U.S.; most was available for domestic needs without repatriation tax.
- Key risks include customer concentration and dependence on Hospira, intense competition and pricing pressure, CLAVE patent expirations beginning in 2014, reliance on manufacturing facilities in Mexico and Slovakia, potential supply interruptions, foreign-exchange exposure and regulatory or product-liability events. The company does not hedge foreign-currency exposure.
- Patent litigation against RyMed remained pending. A jury had found infringement and patent validity on specified claims; the court ordered a new trial on one issue, scheduled for May 7, 2012, followed by a bench trial on remaining issues. Management did not expect other routine legal matters to have a material adverse effect.
- The independent auditor gave an unqualified opinion on the financial statements and reported effective internal control over financial reporting at year-end.
Most important facts for investors to verify
- Whether Hospira maintains purchasing levels and distribution access, given its 42% share of revenue and 36% of year-end receivables.
- How FY2012 sales and margins develop in oncology, infusion therapy and competitively pressured critical care.
- How much of FY2011 earnings growth is repeatable after excluding the $14.2 million asset-sale gain and $2.5 million legal settlement.
- The effects of the rebate-reserve restatement and the adequacy of rebate estimates in subsequent periods.
- The outcome and potential financial consequences of the RyMed litigation, and the effect of upcoming patent expirations on CLAVE competition.
- Execution of the Slovakia manufacturing transition, planned capital spending and exposure to Mexico operations, raw-material costs and currency movements.